<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD"><gtr:id>59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD</gtr:id><gtr:name>The Pirbright Institute</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Ash Road</gtr:line1><gtr:line2>Pirbright</gtr:line2><gtr:line4>Woking</gtr:line4><gtr:line5>Surrrey</gtr:line5><gtr:postCode>GU24 0NF</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD"><gtr:id>59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD</gtr:id><gtr:name>The Pirbright Institute</gtr:name><gtr:address><gtr:line1>Ash Road</gtr:line1><gtr:line2>Pirbright</gtr:line2><gtr:line4>Woking</gtr:line4><gtr:line5>Surrrey</gtr:line5><gtr:postCode>GU24 0NF</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/AA7C2088-C4E9-4E2B-A16E-8757A07E9748"><gtr:id>AA7C2088-C4E9-4E2B-A16E-8757A07E9748</gtr:id><gtr:firstName>Donald</gtr:firstName><gtr:surname>King</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/66A1D773-B5EC-42B7-96C9-5F57EFFF97C3"><gtr:id>66A1D773-B5EC-42B7-96C9-5F57EFFF97C3</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Paton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9C5B6126-27A8-43DD-A3A6-C4E55190175A"><gtr:id>9C5B6126-27A8-43DD-A3A6-C4E55190175A</gtr:id><gtr:firstName>Madhuchhanda</gtr:firstName><gtr:surname>Mahapatra</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B2FF6293-A14C-47A5-A8E8-9886E87A0CF9"><gtr:id>B2FF6293-A14C-47A5-A8E8-9886E87A0CF9</gtr:id><gtr:firstName>Nicholas</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Knowles</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=BB%2FF009186%2F1"><gtr:id>BAA8F39A-8EAC-473E-8556-CD71FA457F92</gtr:id><gtr:title>Identifying epitopes that induce antibody mediated protection against foot-and-mouth disease using reverse genetics</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/F009186/1</gtr:grantReference><gtr:abstractText>Foot-and-mouth disease virus (FMDV) is the causative agent of a highly contagious and economically devastating disease of cloven hoofed domestic and wild animals. FMD is the single most important constraint to international trade in live animals and animal products. The disease is generally controlled by restriction of animal movement and slaughter of infected and in-contact animals which is very costly and unpopular with the public. The recent outbreaks in the United Kingdom in 2001, have significantly increased public awareness of this disease and now there is heightened interest in a strategy that encompasses a 'vaccinate to-live-policy' to complement stamping out as a means of controlling FMD outbreaks. Vaccinated animals produce antibodies which are believed to be important in providing protection against FMD. However, it is not well understood how such antibodies provide protection nor which parts of the virus are most important to be recognised for protection to be optimal. There are many variants of the FMD virus and multiple vaccine strains are needed to protect against all of these. Current methods to select the most appropriate vaccine are not well standardised or reliable because of dependence on antisera raised in animals that do not react to vaccination in a consistent manner. This project will use genetic engineering to construct a series of closely related FMD viruses in which individual features on the surface of the virus shell will have been slightly altered so as to affect antibody recognition. By looking at how well each of these viruses is recognised by antibodies from immune animals and by seeing how well each virus is able to induce a FMD protective immune response, we shall build up a picture of the contribution of each feature to antibody mediated protection. A better understanding of which viral structures are needed to induce a protective immune response will enable us to make accurate and much more rapid predictions of which vaccines have the necessary configurations to offer protection against a new strain of FMDV. This will be of enormous benefit when faced with the decision of whether and where to apply emergency vaccination in the face of a new FMD incursion, since the effectiveness of any vaccination programme is heavily dependent on the speed of its implementation. This knowledge will also be of fundamental value in efforts to develop broader spectrum FMD vaccines that would dramatically improve the prospects for global FMD control and eradication.</gtr:abstractText><gtr:technicalSummary>FMDV causes a highly contagious and economically devastating disease of domestic animals and is generally controlled by vaccination in endemic countries and restriction of animal movement and slaughter of infected and in-contact animals in FMD-free countries. The recent 2001 outbreaks in the United Kingdom have significantly increased public awareness of this disease and now there is heightened interest in a 'vaccinate to-live-policy'. Current FMD vaccines are serotype specific and may fail to protect fully against subtypes. Vaccines therefore have to be selected, currently based on serological match between vaccine strain and field isolate. The mechanism for FMD vaccine induced protection is not clear with respect to both the viral determinants of protection and the role of different immune responses. Antibody mediated protection is believed to be an important component as there is a strong correlation between antibody titre and protection. Various neutralising epitopes have been identified on the surface of the FMD virus using murine MAb escape mutants. In addition there is evidence for the existence of other non-neutralising epitopes that are believed to play a significant role. The relative importance of different epitopes has not been ascertained. This project will help to define viral determinants of antibody mediated protection which will help in the development of sequence-based vaccine selection methods and novel broadly cross-reactive vaccines. Using reverse genetics approach a recombinant virus will be generated that is identical to its parent except that the major antigenic sites will be mutated until no serological cross-reaction between the mutant and its parent. Once it has been shown that the mutant virus does not elicit antibodies able to protect against a parental virus infection, the contribution of the different epitopes to serological recognition and in vivo protection will be established by reconstituting each epitope one at a time.</gtr:technicalSummary><gtr:fund><gtr:end>2014-06-06</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2009-12-07</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>453673</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>The research carried out in this project identified new immunogenic epitopes on the surface of the foot and mouth disease virus that contributes to vaccine induced protection. It extends our knowledge of the surface features of the FMDV capsid known to elicit neutralizing antibodies, and will improve our strategies for vaccine strain selection and rational vaccine design.</gtr:description><gtr:exploitationPathways>The findings could be used to improve the existing vaccine strain selection methods for FMD virus.</gtr:exploitationPathways><gtr:id>0443CEC8-2B10-42F2-A13C-9149D45C8F11</gtr:id><gtr:sectors><gtr:sector>Agriculture, Food and Drink,Education,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>This project has generated capsid sequence data for several FMD virus isolates that has been submitted to public database (NCBI) and are being used by other scientists for their work.</gtr:description><gtr:id>43DE13D5-BC23-46B7-9D3D-B0BB6BDA0525</gtr:id><gtr:impact>This project has generated capsid sequence data for a number of FMD viruses that has been submitted to public database (NCBI) and are being used by other scientists for their work.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>FMD virus capsid sequence</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>https://www.ncbi.nlm.nih.gov/nuccore/KJ415246</gtr:url><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/55C6D345-F0AF-4A34-96F4-51C5BE3A28BF"><gtr:id>55C6D345-F0AF-4A34-96F4-51C5BE3A28BF</gtr:id><gtr:title>Novel antibody binding determinants on the capsid surface of serotype O foot-and-mouth disease virus.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5fc3e6e8a07bbe6344d0ecdbec0580e8"><gtr:id>5fc3e6e8a07bbe6344d0ecdbec0580e8</gtr:id><gtr:otherNames>Asfor AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/89F6F662-073D-46B9-BE90-4E6C2475EBE9"><gtr:id>89F6F662-073D-46B9-BE90-4E6C2475EBE9</gtr:id><gtr:title>Evolutionary non-linear modelling for selecting vaccines against antigenically variable viruses.</gtr:title><gtr:parentPublicationTitle>Bioinformatics (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f03a178310c84d1f0d8aa9131e017a31"><gtr:id>f03a178310c84d1f0d8aa9131e017a31</gtr:id><gtr:otherNames>Rahman T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1367-4803</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9F3C829B-FC41-467F-8912-A55C6001CE6C"><gtr:id>9F3C829B-FC41-467F-8912-A55C6001CE6C</gtr:id><gtr:title>Prediction and characterization of novel epitopes of serotype A foot-and-mouth disease viruses circulating in East Africa using site-directed mutagenesis.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b114cba5cc670a5008fb5728e9f70942"><gtr:id>b114cba5cc670a5008fb5728e9f70942</gtr:id><gtr:otherNames>Bari FD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/337D2E73-34B2-4F13-B9EE-B1A048002641"><gtr:id>337D2E73-34B2-4F13-B9EE-B1A048002641</gtr:id><gtr:title>Tracking the Antigenic Evolution of Foot-and-Mouth Disease Virus.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/84266c39519fdec9b263e1ab8c983276"><gtr:id>84266c39519fdec9b263e1ab8c983276</gtr:id><gtr:otherNames>Reeve R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/42493BDF-3970-48B8-919C-FD39814B8125"><gtr:id>42493BDF-3970-48B8-919C-FD39814B8125</gtr:id><gtr:title>Antigenic and genetic comparison of foot-and-mouth disease virus serotype O Indian vaccine strain, O/IND/R2/75 against currently circulating viruses.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/27d495066860a08816b32799bb097075"><gtr:id>27d495066860a08816b32799bb097075</gtr:id><gtr:otherNames>Mahapatra M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/30C52BC9-F154-4E71-A8DB-F26D5C0E0EC7"><gtr:id>30C52BC9-F154-4E71-A8DB-F26D5C0E0EC7</gtr:id><gtr:title>Genetic basis of antigenic variation in foot-and-mouth disease serotype A viruses from the Middle East.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f509c7b8bc65837d8a2ba7024d7145cb"><gtr:id>f509c7b8bc65837d8a2ba7024d7145cb</gtr:id><gtr:otherNames>Upadhyaya S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E098DCE2-8670-4CCC-AB60-D08FA5A74F46"><gtr:id>E098DCE2-8670-4CCC-AB60-D08FA5A74F46</gtr:id><gtr:title>Emergence of antigenic variants within serotype A FMDV in the Middle East with antigenically critical amino acid substitutions.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/27d495066860a08816b32799bb097075"><gtr:id>27d495066860a08816b32799bb097075</gtr:id><gtr:otherNames>Mahapatra M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A4D4D3EA-A089-4C19-991B-C5E77DAFE201"><gtr:id>A4D4D3EA-A089-4C19-991B-C5E77DAFE201</gtr:id><gtr:title>Genetic and antigenic characterisation of serotype A FMD viruses from East Africa to select new vaccine strains.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b114cba5cc670a5008fb5728e9f70942"><gtr:id>b114cba5cc670a5008fb5728e9f70942</gtr:id><gtr:otherNames>Bari FD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/F009186/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>